미국 · 보도자료 · LTRN · 2026-09-29 12:00
최대 800만 달러 규모 보통주 직접 공모(RD) 추진
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock (or pre-funded warrants
